Table 2.
Baseline results of laboratory tests according to eGFR changes during follow-up. Data are shown as mean ± SD or median (Q1; Q3).
| Laboratory Test | eGFR at the End of Follow-Up | p | |
|---|---|---|---|
| ≤90% of Initial Value (n = 30) | >90% of Initial Value (n = 79) | ||
| Urine albumin, mg/L | 165 (20; 731) | 21 (8; 67) | 0.001 |
| uACR, mg/g | 194 (28; 1066) | 26 (11; 159) | 0.001 |
| Serum creatinine, µmol/L | 142 (111; 205) | 127 (97; 168) | 0.09 |
| eGFR (CKD-EPICr), mL/min/1.73m2 | 38 (31; 54) | 49 (38; 70) | 0.038 |
| Urine NGAL, µg/L | 17.8 (8.0; 30.0) | 8.9 (4.0; 21.6) | 0.020 |
| Urine NGAL/creatinine, µg/g | 25.2 (9.8; 58.5) | 13.2 (5.6; 22.7) | 0.015 |
| Urine MMP 9-NGAL complex, µg/L * | 0.255 (0.141; 0.584) | 0.216 (0.13; 0.681) | 0.8 |
| Urine MMP 9-NGAL/creatinine, µg/g * | 0.35 (0.21; 1.71) | 0.39 (0.23; 1.29) | 0.9 |
| Hemoglobin, g/dl | 12.4 (11.1; 13.4) | 13.2 (12.6; 14.5) | 0.005 |
| White blood count, ×103/µL | 7.50 (5.80; 8.38) | 7.07 (5.97; 8.51) | 0.8 |
| Platelet count, ×103/µL | 196 ± 53 | 211 ± 56 | 0.2 |
| Triglycerides, mmol/L | 1.64 (1.28; 2.12) | 1.58 (1.21; 2.12) | 0.9 |
| Total cholesterol, mmol/L | 5.17 (4.20; 5.66) | 4.91 (4.21; 5.73) | 0.7 |
| Uric acid, mmol/L | 378 (342; 431) | 379 (334; 431) | 0.9 |
| C-reactive protein, mg/L | 1.84 (1.00; 4.44) | 1.41 (1.00; 2.99) | 0.5 |
| Serum albumin, g/L | 42 (40; 44) | 44 (43; 46) | 0.002 |
| Glucose, mmol/L | 5.55 (5.16; 6.06) | 5.44 (5.07; 6.02) | 0.7 |
* Available in 77 patients (19 with decreasing eGFR and 55 with non-decreasing eGFR). eGFR, estimated glomerular filtration rate; CKD-EPICr [33], Chronic Kidney Disease—Epidemiology Collaboration equation based on serum creatinine; NGAL, neutrophil gelatinase-associated lipocalin; MMP 9, matrix metalloproteinase 9; uACR, urinary albumin to creatinine ratio.